CAR T-cell Therapy | Specialty

The OncLive CAR T-cell therapy condition center page is a comprehensive resource for clinical news and expert insights on FDA-approved and investigational CAR T-cell products in hematologic malignancies, specifically acute lymphoblastic leukemia, non-Hodgkin lymphoma, and multiple myeloma. CAR T-cell research in solid tumors is also under exploration. This page features news articles, interviews in written and video format, and podcasts that focus on updates with CAR T-cell therapy and the ongoing research with this type of treatment.

ASCO Studies Refine CAR T Cell Use

June 7th 2018

Several studies presented at the 2018 ASCO Annual Meeting helped further refine and inform treatment strategies for the budding class of CAR T-cell therapies, with a focus on predicting adverse events and optimizing efficacy.

bb2121 Adds Nearly 1 Year of PFS for Heavily Pretreated Myeloma

June 2nd 2018

bb2121 had a median progression-free survival of 11.8 months and a median duration of response of 10.8 months for patients with relapsed/refractory heavily pretreated multiple myeloma.

CAR T-Cell Therapy in DLBCL: Centers of Excellence

May 25th 2018

DLBCL: Managing Toxicities of CAR T-Cell Therapy

May 25th 2018

Response Data from the JULIET Trial in DLBCL

May 25th 2018

Lymphodepletion for CAR T-Cell Therapies in DLBCL

May 25th 2018

Selecting from CAR T-Cell Therapies in DLBCL

May 25th 2018

Candidates for CAR T-Cell Therapy in DLBCL

May 25th 2018

Future Outlook of CAR T-Cell Therapy for DLBCL

May 25th 2018

Practical Implications of CAR T-Cell Therapy

May 25th 2018

Clinical Significance of the JULIET Trial

May 25th 2018

Emerging CAR T-Cell Therapies

May 25th 2018

Initial Steps for Treatment of DLBCL

May 25th 2018

Dr. Perl on Remaining Challenges with CAR T-Cell Therapy

May 23rd 2018

Alexander E. Perl, MD, associate professor of medicine, University of Pennsylvania, discusses remaining challenges with chimeric antigen receptor (CAR) T-cell therapy.

CAR T-Cell Therapy, Checkpoint Inhibitors Making Waves Across Hematologic Malignancies

May 18th 2018

Anas Younes, MD, discusses the current and future state of CAR T-cell therapies and immune checkpoint inhibitors in the landscape of hematologic malignancies.

CAR T-Cell Payment Codes Don't Address True Cost

May 17th 2018

CMS's initial payment codes for CAR T-cell therapies are opposed by the medical community on the basis that they would be cumbersome to implement and wouldn't reflect the full amount of care delivered to each patient.

Dr. Brentjens Discusses Targets for CAR T-Cell Therapy

May 8th 2018

Renier J. Brentjens, MD, PhD, associate professor, chief, Cellular Therapeutics Center, Memorial Sloan Kettering Cancer Center, discusses targets for chimeric antigen receptor (CAR) T-cell therapy.

Tisagenlecleucel Safety, Efficacy Promising in Pediatric Down Syndrome and ALL

May 4th 2018

A first-time study of chimeric antigen receptor T-cell therapy in youths with Down syndrome-associated relapsed/refractory (r/r) acute lymphoblastic leukemia produced high remission rates and toxicity results that were similar to those observed in patients with r/r ALL.

Selective T-Cell Depletion Improves Engraftment, Reduces GVHD in Pediatric/AYA Leukemia

May 4th 2018

Eliminating T cells carrying alpha and beta chains of the T-cell receptor reduced the risk for graft-versus-host-disease while producing "excellent" engraftment kinetics for young patients with acute leukemia who underwent hematopoietic stem cell transplant.

Memory-Related Genes May Overcome Resistance to CAR T-Cell Therapy in CLL

May 3rd 2018

Results from a recent study may show why some patients with chronic lymphocytic leukemia are resistant to tisagenlecleucel, while potentially offering a pathway to enhance patient response.